Erratum: Biological activities of pargamicin A, a novel cyclic peptide antibiotic from Amycolatopsis sp. (The Journal of Antibiotics (2010) 63 (279 283) DOI: 10.1038/ja.2010.29);Biological activities of pargamicin A, a novel cyclic peptide antibiotic from Amycolatopsis sp.

Journal of Antibiotics

Volumn 63, Issue 6, 2010, Pages 279-283

  Hashizume, Hideki ^a   Adachi, Hayamitsu ^a   Igarashi, Masayuki ^a   Nishimura, Yoshio ^a   Akamatsu, Yuzuru ^a  

^a INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

Amycolatopsis sp.; antibacterial; cyclic peptide; MRSA; piperazic acid; VRE

Indexed keywords

DAPTOMYCIN; ERYTHROMYCIN; HABEKACIN; LINEZOLID; PARGAMICIN A; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; CYCLOPEPTIDE; DIAGNOSTIC AGENT; DIBEKACIN; DRUG DERIVATIVE; FLUORESCENT DYE; NOVOBIOCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; CELL MEMBRANE POTENTIAL; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; ACTINOMYCETALES; CELL MEMBRANE; DRUG EFFECT; METABOLISM; MICROBIOLOGICAL EXAMINATION; STAPHYLOCOCCUS AUREUS;

AMYCOLATOPSIS SP.; BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ACTINOMYCETALES; ANTI-BACTERIAL AGENTS; CELL MEMBRANE; DIBEKACIN; ENTEROCOCCUS FAECALIS; FLUORESCENT DYES; MEMBRANE POTENTIALS; MICROBIAL SENSITIVITY TESTS; NOVOBIOCIN; PEPTIDES, CYCLIC; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 77954162572     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2010.37     Document Type: Erratum

References (15)

1. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinone (U-100592 and U-100766), and other oral and parental agents against 203 penicillinsusceptible and -resistant Pneumococci. Antimicrob. Agents Chemother. 40, 481-484 (1996).
2. Robert, J. F. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. 35, 553-559 (1991).
3. George, M. E. et al. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30, 532-535 (1986).
4. Peterson, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E. & Testa, R. T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43, 738-744 (1999).
5. Lee,D.K.et al. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/ dalfopristin and tigecycline against vancomycin-resistant Enterococci (VRE) from clinical isolates in Korea (1998 and 2005). J. Biochem. Mole. Biol. 40, 881-887 (2007).
6. Pillai, S. K. et al. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alternation in MprF. Antimicrob. Agents Chemother. 51, 2223-2225 (2007).
7. Luh,K.L. et al. Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother. 44, 3374-3380 (2000).
8. Besier, S., Ludwig, A., Zander, J., Brade, V. & Wichelhaus, T. A. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52, 1570-1572 (2008).
9. Werner, G., Gfrorer, S., Freige, C., Witte, W. & Klare, I. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J. Antimicrob. Chemother. 61, 1182-1183 (2008).
10. Jones, T. et al. Failure in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alternations in surface charge, membrane phospholipids asymmetry, and drug binding. Antimicrob. Agents Chemother. 52, 269-278 (2008).
11. Peleg, A. Y., Adams, J. & Paterson, D. L. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 2065-2069 (2007).
12. Igarashi, M. et al. A novel cyclic peptide antibiotic from Amycolatopsis sp. J. Antibiot. 61, 387-393 (2008).
13. Higgins, D. L. et al. Telavancin a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agenrts Chemother. 49, 1127-1134 (2005).
14. Williams, J. C. & Bell, R. M. Membrane matrix disruption by melittin. Biochim. Biophys. Acta. 288, 255-262 (1972).
15. Silverman, J. A., Perlmutter, N. G. & Shapiro, H. M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 2538-2544 (2003).